FDA OKs Rifamycin for Travelers’ Diarrhea Caused by Noninvasive E coli – Drug for nerve pain boosts high for opioid abusers.

1999_GraphicImage_061815-piAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA OKs Rifamycin for Travelers’ Diarrhea Caused by Noninvasive E coli – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the US Food and Drug Administration (FDA) approved the broad spectrum, semi-synthetic, orally administered, minimally absorbed antibiotic rifamycin (Aemcolo, Cosmo Technologies, Ltd) for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli not complicated by fever or blood in the stool.

As the most common travel-related illness, travelers’ diarrhea—defined as 3 or more unformed stools in 24 hours—affects about 10% to 40% of individuals who travel each year. Most commonly caused by bacteria found in water, individuals at highest risk are those who travel to most of Asia as well as the Middle East, Africa, Mexico, and Central and South America, according to the FDA.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.